tirzepatide and hypothyroidism Hashimoto's Tirzepatide: Safety and Monitoring Guide Tirzepatide for Hashimoto's Disease: Evidence

The GLP-1 gold rush is getting a lot less photogenic

Here's what the science actually shows.

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist, has shown promising weight-loss effects in previous trials

In animal models of diabetes, the authors show that co-administration of a lipid-lowering drug with a dipeptidyl peptidase-4 inhibitor or a glucagon-like peptide-1 agonist improved glucose tolerance and beta cell mass

Taking Mounjaro and Wegovy at the same time activates identical GLP-1 and GIP receptors, creating dangerous drug overlap rather than synergy

Safe, prescription-based weight loss programs for eligible patients, including GLP-1 options.